13. Change in Venous Clinical Severity Score (VCSS).
| EVLA versus RFA | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| EVLA | RFA | EVLA | RFA | EVLA | RFA | |
| Recovery 2009 mean (SD) 1 month | 4.9 (2.8) | 4.7 (3.1) | 3.2 (1.8) | 2.7 (2.2) | ||
| Rasmussen 2011 mean (SD) 3 yr | 2.68 (2.25) | 2.95 (2.06) | 0.34 (1.3) | 0.44 (1.82) | 3.3 | 3.7 |
| Shepherd 2010 mean (SD) 6 months | 4.7 (2.1) | 5.1 (2.1) | 1.4 (1.8) | 1.4 (1.7) | ||
| Syndor 2017 median (range) 6 months | 5 (2 ‐ 26) | 5 (1 ‐ 20) | 1 (0 ‐ 18) | 1 (0 ‐ 6) | ||
| EVLA versus EVSA | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| EVLA | EVSA | EVLA | EVSA | EVLA | EVSA | |
|
LAST 2014 change after 12 weeks (95% CI) |
not given | not given | not given | not given | ‐2.5 (‐2.1 to ‐2.93) |
all ‐2.9 (‐2.4 to ‐3.5) hIgha ‐2.69 (‐2.34 to ‐3.04) |
| EVLA versus UGFS | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| EVLA | UGFS | EVLA | UGFS | EVLA | UGFS | |
| Rasmussen 2011 mean (SD) 3 yr | 2.68 (2.25) | 2.66 (1.45) | 0.34 (1.3) | 0.15 (0.4) | ||
| EVLA versus CA | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| EVLA | CA | EVLA | CA | EVLA | CA | |
| Calik 2019 mean (SD) 1 yr | 5.8 (1.9) | 5.7 (1.9) | 1.3 (0.9) | 1.3 (0.9) | ||
| EVLA versus MOCA ‐ no data | ||||||
| EVLA versus HL/S (surgery) | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| EVLA |
HL/S (surgery) |
EVLA |
HL/S (surgery) |
EVLA |
HL/S (surgery) |
|
| Rasmussen 2007 mean (SD) 5 yr | 2.8 (1.7) | 2.4 (1.4) | 0.4 (0.9) | 2.4 (1.4) | ||
| Rasmussen 2011 mean (SD) 3 yr | 2.68 (2.25) | 2.75 (1.62) | 0.34 (1.3) | 0.3 (0.5) | ||
| RFA versus UGFS | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| RFA | UGFS | RFA | UGFS | RFA | UGFS | |
| Rasmussen 2011 mean (SD) 3 yr | 2.95 (2.06) | 2.66 (1.45) | 0.44 (1.82) | 0.15 (0.4) | ||
| RFA versus CA | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| RFA | CA | RFA | CA | RFA | CA | |
| Morrison 2015 mean (SD) 3 months | 5.6 (2.6) | 5.5 (2.6) | 2.0 (2.0) | 1.9 (1.6) | ||
| RFA versus MOCA | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| RFA | MOCA | RFA | MOCA | RFA | MOCA | |
| Lane 2017 median (range) 6 months | 5 | 6 | 2 (1 ‐ 5) | 2 (1 ‐ 4) | ||
| MARADONA 2019 median (IQR) 2 yr | individually reported |
individually reported |
individually reported |
individually reported |
4 (3 ‐ 5) | 3 (2 ‐ 5) |
| RFA versus HL/S (surgery) | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| RFA | HL/S (surgery) | RFA | HL/S (surgery) | RFA | HL/S (surgery) | |
| EVOLVeS 2003 mean (SD) 2 yr | 4.8 (0.34) | 4.39 (0.38) | unable to read from graph | |||
| Rasmussen 2011 mean (SD) 3 yr | 2.95 (2.06) | 2.75 (1.62) | 0.44 (1.82) | 0.3 (0.5) | ||
|
Rautio 2002 median (range) 3 yr change ‐ mean (SD) |
4 (4 ‐ 6) | 5 (4 ‐ 9) | ‐ 4.3 (2.3) | ‐4 (‐1.2) | ||
| UGFS versus HL/S (surgery) | ||||||
| Study ‐ final time point | Initial VCSS | Final VCSS | Change in VCSS | |||
| UGFS | HL/S (surgery) | UGFS | HL/S (surgery) | UGFS | HL/S (surgery) | |
| FOAM 2010 mean (SD) 2 yr | 3.2 (1.9) | 3.5 (2.2) | 1.7 (1.2) | 1.9 (1.4) | ‐1.49 | ‐1.75 |
| Rasmussen 2011 mean (SD) 3 yr | 2.66 (1.45) | 2.75 (1.62) | 0.15 (0.4) | 0.3 (0.5) | ||
aHigh dose of steam
CA: cyanoacrylate glue CI: confidence interval EVLA: endovenous laser ablation EVSA: endovenous steam ablation HL/S: high ligation and stripping IQR: interquartile range MOCA: mechanochemical ablation RFA: radiofrequency ablation SD: standard deviation UGFS: ultrasound‐guided foam sclerotherapy yr: year(s)